Preoperative serum C-reactive protein level in non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 3001-3004

  Hara, Masaki ^a   Matsuzaki, Yasunori ^a   Shimuzu, Tetsuya ^a   Tomita, Masaki ^a   Ayabe, Takanori ^a   Enomoto, Yusuke ^a   Onitsuka, Toshio ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

C reactive protein; Inflammatory mediator; Non small cell lung cancer; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREOPERATIVE CARE; SURVIVAL RATE;

EID: 34547761399     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A and Peros G: Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11: 1639-1643, 2005.
2. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y and Kusunoki M: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 49: 970-976, 2004.
3. Gockel I, Dirksen K, Messow CM and Junginger T: Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12: 3746-3750, 2006.
4. Guillem P and Triboulet JP: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18: 146-150, 2005.
5. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K and Takenaka K: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864, 2005.
6. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ and Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082, 1995.
7. Jones JM, McGonigle NC, McAnespie M, Cran GW and Graham AN: Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53: 97-101, 2006.
8. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V and Topuz E: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22: 353-358, 2005.
9. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S and Ochiai T: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248-252, 2003.
10. Nozoe T, Matsumata T, Kitamura M and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338, 1998.
11. Matsuguchi T, Okamura S, Kawasaki C, Shimoda K, Omori F, Hayashi S, Kimura N and Niho Y: Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplification and increased mRNA stability. Eur J Haematol 47: 128-133, 1991.
12. Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T and Saijo N: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 2: 553-559, 1996.
13. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Ueoka H and Tanimoto M: Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 52: 391-398, 2003.
14. Jiao X and Krasna MJ: Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 74: 278-284, 2002.
15. Jee SH, Shen SC, Chiu HC, Tsai WL and Kuo ML: Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 20: 198-208, 2001.
16. Frassanito MA, Cusmai A, Iodice G and Dammacco F: Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97: 483-489, 2001.
17. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89: 227-234, 1997.